Evidence map›Paper›PMID 32994221›Full record

ArticleThe Journal of biological chemistry2020

A physical basis for quantitative ChIP-sequencing.

Bradley M Dickson, Rochelle L Tiedemann, Alison A Chomiak, Evan M Cornett, Robert M Vaughan, Scott B Rothbart

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Ketolysis drives CD8Immunity · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. A new approach for quantifying epigenetic landscapes.The Journal of biological chemistry · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Bradley M DicksonCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, Michigan, USA. Electronic address: bradley.dickson@vai.org.
Rochelle L TiedemannCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, Michigan, USA.
Alison A ChomiakCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, Michigan, USA.
Evan M CornettCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, Michigan, USA; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Robert M VaughanCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, Michigan, USA.
Scott B RothbartCenter for Epigenetics, Van Andel Research Institute, Grand Rapids, Michigan, USA.
Van Andel Institute · US

Funding

Molecular mechanisms of chromatin and epigenetic regulationR35GM124736 · NIGMS · VAN ANDEL RESEARCH INSTITUTE · PI ROTHBART, SCOTT · 2017 to 2021
$2.4M
The Role of the Epigenetic Regulator UHRF1 in Colon TumorigenesisF32CA225043 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI LANCTOT CHOMIAK, ALISON ANN · 2018 to 2020
$191k
DNA methylation regulation through the UHRF1 oncoproteinF99CA245821 · NCI · VAN ANDEL INSTITUTE GRADUATE SCHOOL · PI VAUGHAN, ROBERT MARK · 2019 to 2020
$90k
NCI NIH HHS F32 CA225043NCI NIH HHS F99 CA245821NIGMS NIH HHS R35 GM124736
6 · The paper itself

Abstract

ChIP followed by next-generation sequencing (ChIP-Seq) is a key technique for mapping the distribution of histone posttranslational modifications (PTMs) and chromatin-associated factors across genomes. There is a perceived challenge to define a quantitative scale for ChIP-Seq data, and as such, several approaches making use of exogenous additives, or "spike-ins," have recently been developed. Herein, we report on the development of a quantitative, physical model defining ChIP-Seq. The quantitative scale on which ChIP-Seq results should be compared emerges from the model. To test the model and demonstrate the quantitative scale, we examine the impacts of an EZH2 inhibitor through the lens of ChIP-Seq. We report a significant increase in immunoprecipitation of presumed off-target histone PTMs after inhibitor treatment, a trend predicted by the model but contrary to spike-in-based indications. Our work also identifies a sensitivity issue in spike-in normalization that has not been considered in the literature, placing limitations on its utility and trustworthiness. We call our new approach the

Indexed as

Chromatin Immunoprecipitation SequencingSequence Analysis, DNAHumansantibody specificitybiophysicsChIP normalizationChIP-SeqChIP-sequencingchromatin immunoprecipitation (ChiP)epigeneticsmathematical modelingquantitative ChIPquantitative ChIP-Seqspike-in

Identifiers

PMID32994221
PMCPMC7681007
OpenAlexW3091006917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.